Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Clinical Reviews in Allergy & Immunology
Erschienen in: Clinical Reviews in Allergy & Immunology 2/2017

18.06.2016

Regulatory T Cells in Systemic Sclerosis: a Comprehensive Review

verfasst von: Gleb Slobodin, Doron Rimar

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Systemic sclerosis (SSc) is a chronic inflammatory disease with complex pathogenesis, based on the sophisticated interplay of injury to the vascular endothelium, exaggerated tissue regeneration and fibrosis, and extensive immune abnormalities. The role of regulatory T cells (Tregs) in the development of SSc has started being studied during the last decade with new aspects being disclosed continuously, in parallel with the better understanding of Tregs physiology. There is a general agreement in the medical literature regarding the decreased functional capacity of circulating Tregs in SSc. Some patients, particularly those with active disease, may have increased numbers of circulating Tregs, representing the inhibitory response of the immune system to its inappropriate activation or occurring as a compensatory move for Tregs’ decreased suppressive ability. Decreased pool of circulating Tregs can be seen in other SSc patients, with even lower Treg percentages seen in patients with long-standing disease. Skin-resident Tregs are depleted in advanced SSc but can be active and have a role in earlier disease stages. In addition to diminished suppressive ability, Tregs can contribute to SSc evolution by their microenvironment-dependent transformation to pathogenic effector T cells of Th17 or Th2 lineages with respective pro-inflammatory or pro-fibrotic activity. The current data on the effects of existing treatment modalities, including autologous stem cell transplantation, on Tregs function in SSc, is controversial, not being sufficiently elaborated.
Literatur
1.
Barnes J, Mayes MD (2012) Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr Opin Rheumatol 24(2):165–170CrossRefPubMed
2.
Elhai M, Avouac J, Walker UA et al (2016) A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. Ann Rheum Dis 75(1):163–169CrossRefPubMed
3.
Denton CP (2015) Systemic sclerosis: from pathogenesis to targeted therapy. Clin Exp Rheumatol 33(4 Suppl 92):S3–S7PubMed
4.
Krieg T, Takehara K (2009) Skin disease: a cardinal feature of systemic sclerosis. Rheumatology (Oxford) 48(Suppl 3):iii14–iii18
5.
Tyndall AJ, Bannert B, Vonk M et al (2010) Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69(10):1809–1815CrossRefPubMed
6.
Desbois AC, Cacoub P (2016) Systemic sclerosis: an update in 2016. Autoimmun Rev 15:417–426CrossRefPubMed
7.
Meier FM, Frommer KW, Dinser R et al (2012) Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 71:1355–1360CrossRefPubMed
8.
Coghlan JG, Denton CP, Grunig E et al (2014) Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 73:1340–1349CrossRefPubMed
9.
Amaral TN, Peres FA, Lapa AT et al (2013) Neurologic involvement in scleroderma: a systematic review. Semin Arthritis Rheum 43:335–347CrossRefPubMed
10.
Maurer B, Distler A, Suliman YA et al (2014) Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis. Ann Rheum Dis 73:1880–1887CrossRefPubMed
11.
Kawaguchi Y, Suzuki K, Hara M et al (1994) Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis. Ann Rheum Dis 53(8):506–510CrossRefPubMedPubMedCentral
12.
13.
Van Bon L, Affandi AJ, Broen J et al (2014) Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med 370:433–443CrossRefPubMed
14.
Pisitkun P, Deane JA, Difilippantonio MJ et al (2006) Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 312(5780):1669–1672CrossRefPubMed
15.
Eloranta ML, Franck-Larsson K, Lövgren T et al (2010) Type I interferon system activation and association with disease manifestations in systemic sclerosis. Ann Rheum Dis 69(7):1396–1402CrossRefPubMed
16.
Dimitroulas T, Daoussis D, Garyfallos A, Sfikakis PP, Kitas GD (2015) Molecular and cellular pathways as treatment targets for biologic therpaies in systemic sclerosis. Curr Med Chem 22(16):1943–1955CrossRefPubMed
17.
Gottenberg JE, Chiocchia G (2007) Dendritic cells and interferon-mediated autoimmunity. Biochimie 89(6-7):856–871CrossRefPubMed
18.
Huang XL, Wang YJ, Yan JW et al (2015) Role of anti-inflammatory cytokines IL-4 and IL-13 in systemic sclerosis. Inflamm Res 64(3-4):151–159CrossRefPubMed
19.
Liu M, Yang J, Xing X et al (2014) Interleukin-17A promotes functional activation of systemic sclerosis patient-derived dermal vascular smooth muscle cells by extracellular-regulated protein kinases signalling pathway. Arthritis Res Ther 16(6):4223CrossRefPubMedPubMedCentral
20.
Stummvoll GH, Aringer M, Smolen JS et al (2000) Derangement of apoptosis-related lymphocyte homeostasis in systemic sclerosis. Rheumatology (Oxford) 39(12):1341–1350CrossRef
21.
22.
Liston A, Gray DH (2014) Homeostatic control of regulatory T cell diversity. Nat Rev Immunol 14(3):154–165CrossRefPubMed
23.
Chizzolini C, Boin F (2015) The role of the acquired immune response in systemic sclerosis. Semin Immunopathol 37(5):519–528CrossRefPubMed
24.
Ohkura N, Hamaguchi M, Morikawa H et al (2012) T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development. Immunity 37(5):785–799CrossRefPubMed
25.
26.
Miyara M, Yoshioka Y, Kitoh A et al (2009) Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30(6):899–911CrossRefPubMed
27.
Pesenacker AM, Broady R, Levings MK (2014) Control of tissue-localized immune responses by human regulatory T cells. Eur J Immunol 45(2):333–343CrossRefPubMed
28.
29.
Nomura T, Kabashima K, Miyachi Y (2014) The panoply of αβT cells in the skin. J Dermatol Sci 76(1):3–9CrossRefPubMed
30.
Seneschal J, Clark RA, Gehad A et al (2012) Human epidermal Langerhans cells maintain immune homeostasis in skin by activating skin resident regulatory T cells. Immunity 36(5):873–884CrossRefPubMedPubMedCentral
31.
32.
Stary G, Klein I, Bauer W et al (2011) Glucocorticosteroids modify Langerhans cells to produce TGF-β and expand regulatory T cells. J Immunol 186(1):103–112CrossRefPubMed
33.
Chu CC, Ali N, Karagiannis P et al (2012) Resident CD141 (BDCA3) + dendritic cells in human skin produce IL-10 and induce regulatory T cells that suppress skin inflammation. J Exp Med 209(5):935–945CrossRefPubMedPubMedCentral
34.
Tomura M, Honda T, Tanizaki H et al (2010) Activated regulatory T cells are the major T cell type emigrating from the skin during a cutaneous immune response in mice. J Clin Invest 120(3):883–893CrossRefPubMedPubMedCentral
35.
36.
Pesenacker AM, Bending D, Ursu S et al (2013) CD161 defines the subset of FoxP3+ T cells capable of producing proinflammatory cytokines. Blood 121(14):2647–2658CrossRefPubMedPubMedCentral
37.
Duhen T, Duhen R, Lanzavecchia A et al (2012) Functionally distinct subsets of human FOXP3+ Treg cells that phenotypically mirror effector Th cells. Blood 119(19):4430–4440CrossRefPubMedPubMedCentral
38.
McClymont SA, Putnam AL, Lee MR et al (2011) Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol 186(7):3918–3926CrossRefPubMedPubMedCentral
39.
Radstake TR, van Bon L, Broen J et al (2009) Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFbeta expression. PLoS One 4(6):e5981CrossRefPubMedPubMedCentral
40.
Simonetta F, Chiali A, Cordier C et al (2010) Increased CD127 expression on activated FOXP3 + CD4+ regulatory T cells. Eur J Immunol 40(9):2528–2538CrossRefPubMed
41.
Giovannetti A, Rosato E, Renzi C et al (2010) Analyses of T cell phenotype and function reveal an altered T cell homeostasis in systemic sclerosis. Correlations with disease severity and phenotypes. Clin Immunol 137(1):122–133CrossRefPubMed
42.
Slobodin G, Ahmad MS, Rosner I et al (2010) Regulatory T cells (CD4(+)CD25(bright)FoxP3(+)) expansion in systemic sclerosis correlates with disease activity and severity. Cell Immunol 261(2):77–80CrossRefPubMed
43.
Liu X, Gao N, Li M et al (2013) Elevated levels of CD4(+)CD25(+)FoxP3(+) T cells in systemic sclerosis patients contribute to the secretion of IL-17 and immunosuppression dysfunction. PLoS One 8(6):e64531CrossRefPubMedPubMedCentral
44.
Jiang N, Li M, Zeng X (2014) Correlation of Th17 cells and CD4+CD25+ regulatory T cells with clinical parameters in patients with systemic sclerosis. Chin Med J (Engl) 127(20):3557–3561
45.
Rodríguez-Reyna TS, Furuzawa-Carballeda J, Cabiedes J et al (2012) Th17 peripheral cells are increased in diffuse cutaneous systemic sclerosis compared with limited illness: a cross-sectional study. Rheumatol Int 32(9):2653–2660CrossRefPubMed
46.
Klein S, Kretz CC, Krammer PH et al (2010) CD127(low/-) and FoxP3(+) expression levels characterize different regulatory T-cell populations in human peripheral blood. J Invest Dermatol 130(2):492–499CrossRefPubMed
47.
Klein S, Kretz CC, Ruland V et al (2011) Reduction of regulatory T cells in skin lesions but not in peripheral blood of patients with systemic scleroderma. Ann Rheum Dis 70(8):1475–1481CrossRefPubMed
48.
Banica L, Besliu A, Pistol G et al (2009) Quantification and molecular characterization of regulatory T cells in connective tissue diseases. Autoimmunity 42(1):41–49CrossRefPubMed
49.
Antiga E, Quaglino P, Bellandi S et al (2010) Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea. Br J Dermatol 162(5):1056–1063CrossRefPubMed
50.
Papp G, Horvath IF, Barath S et al (2011) Altered T-cell and regulatory cell repertoire in patients with diffuse cutaneous systemic sclerosis. Scand J Rheumatol 40(3):205–210CrossRefPubMed
51.
Fenoglio D, Battaglia F, Parodi A et al (2011) Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis. Clin Immunol 139(3):249–257CrossRefPubMed
52.
Cordiali-Fei P, Mussi A, D’Agosto G et al (2013) Assessment of T regulatory cells and expanded profiling of autoantibodies may offer novel biomarkers for the clinical management of systemic sclerosis and undifferentiated connective tissue disease. Clin Dev Immunol 2013:390563CrossRefPubMedPubMedCentral
53.
Reiff A, Weinberg KI, Triche T et al (2013) T lymphocyte abnormalities in juvenile systemic sclerosis patients. Clin Immunol 149(1):146–155CrossRefPubMed
54.
Mathian A, Parizot C, Dorgham K et al (2012) Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions. Ann Rheum Dis 71(7):1227–1234CrossRefPubMed
55.
Kataoka H, Yasuda S, Fukaya S et al (2015) Decreased expression of Runx1 and lowered proportion of Foxp3+ CD25+ CD4+ regulatory T cells in systemic sclerosis. Mod Rheumatol 25(1):90–95CrossRefPubMed
56.
Michels-van Amelsfort JM, Walter GJ, Taams LS (2011) CD4 + CD25+ regulatory T cells in systemic sclerosis and other rheumatic diseases. Expert Rev Clin Immunol 7(4):499–514CrossRefPubMed
57.
Antiga E, Fabbri P, Caproni M (2010) Immunosuppressive therapy may affect the number of circulating regulatory cells in systemic sclerosis: pay attention to the patient selection criteria. Cell Immunol 264(2):186CrossRefPubMed
58.
59.
Papp G, Horvath IF, Barath S et al (2012) Immunomodulatory effects of extracorporeal photochemotherapy in systemic sclerosis. Clin Immunol 142(2):150–159CrossRefPubMed
60.
Papp G, Barath S, Szegedi A et al (2012) The effects of extracorporeal photochemotherapy on T cell activation and regulatory mechanisms in patients with systemic sclerosis. Clin Rheumatol 31(9):1293–1299CrossRefPubMed
61.
Tsukamoto H, Nagafuji K, Horiuchi T et al (2011) Analysis of immune reconstitution after autologous CD34+ stem/progenitor cell transplantation for systemic sclerosis: predominant reconstitution of Th1 CD4+ T cells. Rheumatology (Oxford) 50(5):944–952CrossRef
62.
Baraut J, Grigore EI, Jean-Louis F et al (2014) Peripheral blood regulatory T cells in patients with diffuse systemic sclerosis (SSc) before and after autologous hematopoietic SCT: a pilot study. Bone Marrow Transplant 49(3):349–354CrossRefPubMed
63.
Szodoray P, Varoczy L, Papp G et al (2012) Immunological reconstitution after autologous stem cell transplantation in patients with refractory systemic autoimmune diseases. Scand J Rheumatol 41(2):110–115CrossRefPubMed
64.
Delemarre EM, van den Broek T, Mijnheer G et al (2016) Autologous stem cell transplantation aids autoimmune patients by functional renewal and TCR diversification of regulatory T cells. Blood 127(1):91–101CrossRefPubMed
65.
Broen JC, Wolvers-Tettero IL, Geurts-van Bon L et al (2010) Skewed X chromosomal inactivation impacts T regulatory cell function in systemic sclerosis. Ann Rheum Dis 69(12):2213–2216CrossRefPubMed
66.
Wang YY, Wang Q, Sun XH et al (2014) DNA hypermethylation of the forkhead box protein 3 (FOXP3) promoter in CD4+ T cells of patients with systemic sclerosis. Br J Dermatol 171(1):39–47CrossRefPubMed
67.
Giovannetti A, Maselli A, Colasanti T et al (2013) Autoantibodies to estrogen receptor α in systemic sclerosis (SSc) as pathogenetic determinants and markers of progression. PLoS One 8(9):e74332CrossRefPubMedPubMedCentral
68.
Rimar D, Nov Y, Rosner I et al (2015) Semaphorin 3A: an immunoregulator in systemic sclerosis. Rheumatol Int 35(10):1625–1630CrossRefPubMed
69.
70.
Liu M, Wu W, Sun X, et al. (2016) New insights into CD4(+) T cell abnormalities in systemic sclerosis. Cytokine Growth Factor Rev 28:31–36
71.
Yang X, Yang J, Xing X et al (2014) Increased frequency of Th17 cells in systemic sclerosis is related to disease activity and collagen overproduction. Arthritis Res Ther 16(1):R4CrossRefPubMedPubMedCentral
72.
MacDonald KG, Dawson NA, Huang Q et al (2015) Regulatory T cells produce profibrotic cytokines in the skin of patients with systemic sclerosis. J Allergy Clin Immunol 135(4):946, e9 CrossRefPubMed
Metadaten
Titel
Regulatory T Cells in Systemic Sclerosis: a Comprehensive Review
verfasst von
Gleb Slobodin
Doron Rimar
Publikationsdatum
18.06.2016
Verlag
Springer US
Erschienen in
Clinical Reviews in Allergy & Immunology / Ausgabe 2/2017
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-016-8563-6

Weitere Artikel der Ausgabe 2/2017

Clinical Reviews in Allergy & Immunology 2/2017 Zur Ausgabe

ReviewPaper

Molecular and Immunological Basis of Tubulo-Interstitial Injury in Lupus Nephritis: a Comprehensive Review

ReviewPaper

Epigenetic Variability of CD4+CD25+ Tregs Contributes to the Pathogenesis of Autoimmune Diseases

ReviewPaper

Review of Mouse Models of Graves’ Disease and Orbitopathy—Novel Treatment by Induction of Tolerance

ReviewPaper

CD20-Mimotope Peptide Active Immunotherapy in Systemic Lupus Erythematosus and a Reappraisal of Vaccination Strategies in Rheumatic Diseases

ReviewPaper

The Clinical Relevance of Anti-DFS70 Autoantibodies

ReviewPaper

Beyond Genetics: What Causes Type 1 Diabetes

Neu im Fachgebiet HNO

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Eingreifen von Umstehenden rettet vor Erstickungstod

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Real-World-Daten sprechen eher für Dupilumab als für Op.

14.05.2024 Rhinosinusitis Nachrichten

Zur Behandlung schwerer Formen der chronischen Rhinosinusitis mit Nasenpolypen (CRSwNP) stehen seit Kurzem verschiedene Behandlungsmethoden zur Verfügung, darunter Biologika, wie Dupilumab, und die endoskopische Sinuschirurgie (ESS). Beim Vergleich der beiden Therapieoptionen war Dupilumab leicht im Vorteil.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise